statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced...

MindMed to be Included in Russell 2000 and Russell 3000 Indexes

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today...

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...

Psychedelic Stocks Hit With Bad Trip After FDA Advisers Reject MDMA Treatment For PTSD

Psychedelic Stocks Hit With Bad Trip After FDA Advisers Reject MDMA Treatment For PTSD

 Psychedelic stocks were battered in premarket trading after a panel of experts advising the Food...

MindMed to Participate in June Conferences

MindMed to Participate at May Investor Conferences

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders...

MindMed Reports First Quarter 2024 Financial Results and Business Updates

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented...

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Volume	763,928.00
52-Wk High	$12.22
52-Wk Low	$2.41

MNMD Mind Medicine Inc - Ordinary Shares (Sub Voting)

About

Feed

News

Sentiment

Earnings

Fundamentals